<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7515a8d5-2d6c-4911-93bc-031e8d116fdf,g:2d116408-a8e7-49d2-ad61-f1d93a37b194-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_18ac5f7c-a967-4cf4-9252-6ada301c430b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de708e6b-b8cc-4ef8-98d4-6f95f18b5e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18ac5f7c-a967-4cf4-9252-6ada301c430b" xlink:to="loc_us-gaap_StockholdersEquity_de708e6b-b8cc-4ef8-98d4-6f95f18b5e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dbd53d0e-e852-4bba-86ba-e367d304e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18ac5f7c-a967-4cf4-9252-6ada301c430b" xlink:to="loc_us-gaap_Liabilities_dbd53d0e-e852-4bba-86ba-e367d304e670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9e7e7e9f-d9df-43c2-b3fd-c871c4837074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18ac5f7c-a967-4cf4-9252-6ada301c430b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9e7e7e9f-d9df-43c2-b3fd-c871c4837074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5f99fafb-746e-44cc-aa64-00e8ddc218ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableNoncurrent_47689c21-cf53-4073-819a-b442c40f3981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5f99fafb-746e-44cc-aa64-00e8ddc218ca" xlink:to="loc_us-gaap_GrantsReceivableNoncurrent_47689c21-cf53-4073-819a-b442c40f3981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6be8462b-ea7d-4104-865a-1d5684cf1411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5f99fafb-746e-44cc-aa64-00e8ddc218ca" xlink:to="loc_us-gaap_Goodwill_6be8462b-ea7d-4104-865a-1d5684cf1411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa662391-8e36-4590-b383-f5d70f84e434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5f99fafb-746e-44cc-aa64-00e8ddc218ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fa662391-8e36-4590-b383-f5d70f84e434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22aab328-ab2e-484a-99e4-ed788fd050ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5f99fafb-746e-44cc-aa64-00e8ddc218ca" xlink:to="loc_us-gaap_AssetsCurrent_22aab328-ab2e-484a-99e4-ed788fd050ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d6f4de7-a21c-4fa7-b834-3b4cba5b12e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9bcc4c90-a052-40ac-bf89-ded33d3fb6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f4de7-a21c-4fa7-b834-3b4cba5b12e5" xlink:to="loc_us-gaap_PreferredStockValue_9bcc4c90-a052-40ac-bf89-ded33d3fb6d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59b0d544-6224-4cf8-9cfa-54c588b2e0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f4de7-a21c-4fa7-b834-3b4cba5b12e5" xlink:to="loc_us-gaap_CommonStockValue_59b0d544-6224-4cf8-9cfa-54c588b2e0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6d9161e3-366b-4486-aae1-34d734c7efb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f4de7-a21c-4fa7-b834-3b4cba5b12e5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6d9161e3-366b-4486-aae1-34d734c7efb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b0e37f0-4055-4c21-8702-db47da409f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f4de7-a21c-4fa7-b834-3b4cba5b12e5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b0e37f0-4055-4c21-8702-db47da409f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a904d434-e4c3-4910-81a8-41932436af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e17d09e2-7110-4162-8d36-26001350a985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a904d434-e4c3-4910-81a8-41932436af2a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e17d09e2-7110-4162-8d36-26001350a985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d564b10e-12cf-432c-b264-1d7ba5a7b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a904d434-e4c3-4910-81a8-41932436af2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d564b10e-12cf-432c-b264-1d7ba5a7b134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e65b5778-1b87-4029-9398-40279c3ab157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_b28e8865-0e74-4264-80ff-098a4c112405" xlink:href="flks-20220630.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e65b5778-1b87-4029-9398-40279c3ab157" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_b28e8865-0e74-4264-80ff-098a4c112405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7201e319-db62-4d17-8c92-9cedc364b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e65b5778-1b87-4029-9398-40279c3ab157" xlink:to="loc_us-gaap_AccountsPayableCurrent_7201e319-db62-4d17-8c92-9cedc364b8b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="flks-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d926ac35-9f46-4ff2-abe8-c4c3a5bb2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e0e7bf85-e03e-427d-8fb3-5f3989bd9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d926ac35-9f46-4ff2-abe8-c4c3a5bb2db8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e0e7bf85-e03e-427d-8fb3-5f3989bd9c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1a8c47a3-6d68-4ee6-8998-e1a1d031bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8ecdd0d1-86e9-4744-98c3-7a8e70bfab77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1a8c47a3-6d68-4ee6-8998-e1a1d031bc3a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8ecdd0d1-86e9-4744-98c3-7a8e70bfab77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fa6aecb2-f7b7-454f-a679-733b5c061bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1a8c47a3-6d68-4ee6-8998-e1a1d031bc3a" xlink:to="loc_us-gaap_OperatingIncomeLoss_fa6aecb2-f7b7-454f-a679-733b5c061bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e485723d-770c-4ee8-ad20-d0d03a6536db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_1a8c47a3-6d68-4ee6-8998-e1a1d031bc3a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e485723d-770c-4ee8-ad20-d0d03a6536db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e10c0c54-583f-417e-913c-e15b26e42596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b72d6b38-966d-4ebb-bfd9-2d09e9261e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e10c0c54-583f-417e-913c-e15b26e42596" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b72d6b38-966d-4ebb-bfd9-2d09e9261e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9b865ca3-a2b8-4ea6-b2f1-ff570f149de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e10c0c54-583f-417e-913c-e15b26e42596" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9b865ca3-a2b8-4ea6-b2f1-ff570f149de7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b39e5f7e-36de-4a57-b174-874a725945ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1713552e-12dd-4f92-b246-e15d66dd361c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b39e5f7e-36de-4a57-b174-874a725945ca" xlink:to="loc_us-gaap_OperatingExpenses_1713552e-12dd-4f92-b246-e15d66dd361c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af0f8ffa-6070-407c-9ca7-030458bafed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b39e5f7e-36de-4a57-b174-874a725945ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af0f8ffa-6070-407c-9ca7-030458bafed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="flks-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54f9318b-57d9-4890-8d3e-3423469a37a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_f18080fb-7cbd-41cd-ab33-94ef642fb47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54f9318b-57d9-4890-8d3e-3423469a37a7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_f18080fb-7cbd-41cd-ab33-94ef642fb47f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7f81a9d8-79f7-49d1-927d-7bc8b47b07b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54f9318b-57d9-4890-8d3e-3423469a37a7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7f81a9d8-79f7-49d1-927d-7bc8b47b07b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_3406a0b5-0f38-4cc2-b52e-bbfcca4db923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54f9318b-57d9-4890-8d3e-3423469a37a7" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_3406a0b5-0f38-4cc2-b52e-bbfcca4db923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a9adb34c-8e36-43fa-bf03-913994e85a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_9f52987d-14a9-457d-aa51-93b1debabe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a9adb34c-8e36-43fa-bf03-913994e85a2c" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_9f52987d-14a9-457d-aa51-93b1debabe5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eb31480-dfdf-4066-b684-ebe8b1706d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eb31480-dfdf-4066-b684-ebe8b1706d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_40aafed9-fe49-44c1-b3db-500084382940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_40aafed9-fe49-44c1-b3db-500084382940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2e7b50c7-4fcb-4eab-96e8-b7b536385c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2e7b50c7-4fcb-4eab-96e8-b7b536385c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d51c52b3-3e0c-46ee-8da0-5e36829e5789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_NetIncomeLoss_d51c52b3-3e0c-46ee-8da0-5e36829e5789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_fe376a1c-9a95-482b-8755-f1d2ae8e4ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_fe376a1c-9a95-482b-8755-f1d2ae8e4ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e00bc5c9-a7ae-4d57-81ed-5548ffff33ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e00bc5c9-a7ae-4d57-81ed-5548ffff33ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b91578b5-3244-4cf2-ad74-f4870be2660f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_ShareBasedCompensation_b91578b5-3244-4cf2-ad74-f4870be2660f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_acb62847-a88a-433a-942d-1ae6cb6b3127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_acb62847-a88a-433a-942d-1ae6cb6b3127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2446d0c6-03d2-433d-9fb6-7b4d4ef85305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac99a860-4760-4345-8dd2-870ac9588896" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2446d0c6-03d2-433d-9fb6-7b4d4ef85305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a249ae00-fab9-40d7-a0c3-808b57e0e0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f8b7f7c-0dda-4375-9158-36377627555c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a249ae00-fab9-40d7-a0c3-808b57e0e0b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f8b7f7c-0dda-4375-9158-36377627555c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_193cadc1-73d9-403a-94ac-f70db7310f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a249ae00-fab9-40d7-a0c3-808b57e0e0b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_193cadc1-73d9-403a-94ac-f70db7310f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0a7400a2-f449-4fe2-bde1-c3fe4298f67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a249ae00-fab9-40d7-a0c3-808b57e0e0b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0a7400a2-f449-4fe2-bde1-c3fe4298f67c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20220630.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4229c2-50e8-4650-b2af-710126ffb141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c01220e7-9617-46ea-b614-24fc26140cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4229c2-50e8-4650-b2af-710126ffb141" xlink:to="loc_us-gaap_OtherAssetsCurrent_c01220e7-9617-46ea-b614-24fc26140cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_7f2c8e04-dff6-434b-bd1f-f498f2005165" xlink:href="flks-20220630.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4229c2-50e8-4650-b2af-710126ffb141" xlink:to="loc_flks_PrepaidClinicalTrialExpense_7f2c8e04-dff6-434b-bd1f-f498f2005165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1cb5a3e5-2055-4f33-a033-83422b35c82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4229c2-50e8-4650-b2af-710126ffb141" xlink:to="loc_us-gaap_PrepaidInsurance_1cb5a3e5-2055-4f33-a033-83422b35c82f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
